First Patient Enrolled in NIH Phase 3 Trial to Evaluate Potential COVID-19 Hyperimmune Medicine

Take the Rare Disease Day Quiz!

Test your knowledge about rare diseases, which affect more people than you think.

CSL Half Year Results 2020-21

CSL Delivers Net Profit of Over $ 1.8 Billion

What to Tell the Kids About COVID-19?

A walk to kindergarten with a group of 5-year-olds gave a CSL Behring scientist an idea for a timely children’s book.

CSL COVID19 Update

CSL continues to provide medicines to patients around the world.

What is a Phase III clinical trial?

A potential hyperimmune treatment for COVID-19 reaches a regulatory milestone in testing its efficacy and safety.

First Patient Enrolled to Evaluate Potential COVID-19 Hyperimmune Medicine

As co-leader, CSL Behring is very actively involved in this project. The product for the clinical trial phase 3 was manufactu…

Opening of New Manufacturing Facility in Bern

CSL Behring had a small celebration to mark the grand opening of the facility,

Expansion Nears Completion in Switzerland

CSL Behring validates new production capacity in Bern.

CSL Delivers Net Profit of Over $2.1 Billion

CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a reported net profit after tax of $2,103 million (1) for the 12 months en…